 | Up a level |
Ossenkoppele, G J; Breems, D A; Stuessi, G; van Norden, Y; Bargetzi, M; Biemond, B J; A von dem Borne, P; Chalandon, Y; Cloos, J; Deeren, D; Fehr, M; Gjertsen, B; Graux, C; Huls, G; Janssen, J J J W; Jaspers, A; Jongen-Lavrencic, M; de Jongh, E; Klein, S K; van der Klift, M; ... (2020). Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS. Leukemia, 34(7), pp. 1751-1759. Nature Publishing Group 10.1038/s41375-020-0725-0
Versluis, J; In 't Hout, F E M; Devillier, R; van Putten, W L J; Manz, M G; Vekemans, M-C; Legdeur, M-C; Passweg, J R; Maertens, J; Kuball, J; Biemond, B J; Valk, P J M; van der Reijden, B A; Meloni, G; Schouten, H C; Vellenga, E; Pabst, Thomas; Willemze, R; Löwenberg, B; Ossenkoppele, G; ... (2017). Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio. Leukemia, 31(1), pp. 26-33. Nature Publishing Group 10.1038/leu.2016.183
Cornelissen, J J; Versluis, J; Passweg, Jakob; van Putten, W L J; Manz, M G; Maertens, J; Beverloo, H B; Valk, P J M; van Marwijk Kooy, M; Wijermans, P W; Schaafsma, M R; Biemond, B J; Vekemans, M-C; Breems, D A; Verdonck, L F; Fey, Martin; Jongen-Lavrencic, M; Janssen, J J W M; Huls, G; Kuball, J; ... (2015). Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years. Leukemia, 29(5), pp. 1041-1050. Nature Publishing Group 10.1038/leu.2014.332
